Percutaneous Paravalvular Leak Closure

Register or Login to View PDF Permissions
Permissions× For commercial reprint enquiries please contact Springer Healthcare:

For permissions and non-commercial reprint enquiries, please visit to start a request.

For author reprints, please email
Average (ratings)
No ratings
Your rating


Symptomatic paravalvular leak (PVL) complicates up to 12 % of surgical valve replacements. When patients present with congestive heart failure and/or haemolysis, reoperation for repeat valve replacement may be undertaken, but presents greater risk and lower likelihood of success than the initial operation. Therefore, percutaneous approaches to PVL closure have been developed by specialists in structural cardiac intervention. Large series demonstrate high levels of procedural success and promising clinical outcomes for this complex intervention. A thorough understanding of multimodality imaging is necessary for the diagnosis of PVL and the safe and successful performance of these closure procedures.

Disclosure:The author has no conflicts of interest to declare.



Correspondence Details:Samir R Kapadia, Heart and Vascular Institute, Cleveland Clinic, 9500 Euclid Avenue, Desk J2-3, Cleveland, OH 44195, US. E:

Copyright Statement:

The copyright in this work belongs to Radcliffe Medical Media. Only articles clearly marked with the CC BY-NC logo are published with the Creative Commons by Attribution Licence. The CC BY-NC option was not available for Radcliffe journals before 1 January 2019. Articles marked ‘Open Access’ but not marked ‘CC BY-NC’ are made freely accessible at the time of publication but are subject to standard copyright law regarding reproduction and distribution. Permission is required for reuse of this content.

Among patients undergoing surgical valve replacement, 1–5 % of patients with an aortic valve replacement (AVR) and 2–12 % with a mitral valve replacement (MVR) may develop paravalvular regurgitation or ‘leak’ (PVL).1–3 In the era of transcatheter aortic valve replacement (TAVR) with first-generation balloon expandable valves, up to 17 % of patients may be left with moderate or severe PVL, also referred to as paravalvular aortic regurgitation (PAR).4 Risk factors for PVL in patients undergoing surgical valve replacement include the use of mechanical valves, severe calcification of the valve annulus, or valve replacement for infectious endocarditis. Similar factors contribute to PVL in the post-TAVR setting, as well as improper pre-procedural valve sizing.5

The majority of patients who have symptomatic PVL present with congestive heart failure (CHF) (85 %), and a significant number may have haemolysis (50 %).6,7 Patients who fail medical therapy directed at CHF and/or haemolysis (erythropoietic agents, blood transfusion) should be considered for redo open-heart surgery (OHS) or percutaneous PVL closure. Re-operation must be approached cautiously, as redo surgery usually carries greater risk than a first operation, and recurrence of PVL may be seen in more than one-third of patients who undergo redo OHS for PVL.6

As a result, percutaneous PVL closure has recently gained greater favour. First reported in 1992, this procedure has been slowly evolving and is now successfully performed in a number of centres with significant experience in structural cardiac intervention.8–12 In this review, we will discuss the imaging diagnosis of PVL and data supporting percutaneous closure, as well as highlight the procedural techniques to accomplish PVL closure.

In patients with prior valve replacement, symptoms of CHF or haemolysis should merit further evaluation for PVL. Transthoracic echocardiography (TTE) is important to establish ventricular function and overall valve assessment. It is important to understand, however, that prosthetic valve shielding may not provide an adequate characterisation of PVL and appropriate diagnosis may require further imaging using transoesophageal echocardiography (TOE). In some rare situations, it may be unclear whether the leak is intra- or paravalvular by both TTE and TOE; intracardiac echocardiography (ICE) may be helpful in these situations.

Mitral Paravalvular Leak
The ‘clock face’ nomenclature of the mitral valve (MV) as seen from the left atrium, or ‘surgeon’s view’, facilitates communication among different specialists (see Figure 1). Most PVLs occur anteromedially (10 to 11 o’clock position) and posterolaterally (5 to 6 o’clock position).7,10

Figure 1: Clock Face Designation of the Mitral and Aortic Valves from the Left Atrial Side
Clock Face Designation of the Mitral and Aortic Valves from the Left Atrial Side

As discussed above, TTE may provide the diagnosis and location of PVL (see Figure 2). However, TOE is usually necessary to define the extent of PVL, and understanding the relationship of TOE angles is imperative to an accurate localisation and subsequent treatment (see Figure 3). Three-dimensional (3D) TOE may be beneficial to localise the PVL, but is sometimes limited by shadowing artifact or echo dropout (see Figure 4).

Figure 2: TTT Localization of Mitral PVL
TTT Localization of Mitral PVL
Figure 3: Localisation of Paravalvular Leak Using Transoesophageal Echocardiography
Figure 3: Localisation of Paravalvular Leak Using Transoesophageal Echocardiography

Figure 4: Three-dimensional Transoesophageal Echocardiography Localisation of Mitral Paravalvular Leak Closure
Transoesophageal Echocardiography Localisation of Mitral Paravalvular Leak Closure
Aortic Paravalvular Leak
The clock face of the aortic valve (AV) shares the 12 o’clock position with the MV (see Figure 1). Aortic PVLs are most commonly encountered at the 7 to 11 o’clock position (46 %), followed by the 11 to 3 o’clock position (36 %).10 We find it helpful to also identify the location of the PVL with respect to the native coronary cusp, which more easily translates to the fluoroscopic relationships with which interventionists are familiar. Figure 5 demonstrates the AV in fluoroscopic projection and TOE.

Figure 5: Aortic Paravalvular Leak
Figure 5: Aortic Paravalvular Leak
Outcomes of Percutaneous Paravalvular Leak Closure
While a number of groups have demonstrated successful percutaneous PVL closure in small series’ and case reports, Ruiz and colleagues and Sorajja and colleauges have provided the largest published experiences.9 Ruiz and colleagues performed 57 PVL procedures in 43 patients, with a procedural success of 86.0 % and a 30-day all-cause mortality rate of 5.4 %.11 As a point of reference, surgical series’ have demonstrated a mortality of 6 %.6,10 Haemolysis was a common finding, seen as the reason for the procedure in 14 % and in combination with CHF among 70 %. Despite the fact that 35 % of patients actually developed worsening haemolysis after the procedure, the number of patients requiring erythropoietic agents of regular transfusion decreased from 56 to 5 %. In this series, 10 patients required a redo percutaneous procedure, and two required three procedures total. This not only demonstrates the safety of repeat percutaneous procedures, but the idea that continued valve dehiscence may lead to new or worsening leaks.

Sorajja and colleagues published their short-term outcomes of closure for 141 defects (115 patients, 78 % mitral, 22 % aortic) and long-term outcomes on closure of 154 defects (126 patients).11,13 Heart failure outcomes were substantially improved: despite 93 % of patients presenting with CHF, 72 % had none or minimal dyspnoea at three-year follow-up. Procedural success was enjoyed by 77.0 % of patients, and 8.7 % experienced a major adverse event at 30-days. Importantly, >3+ PVL was seen in only 10 % of patients post-closure. One patient required emergent surgery due to valve interference by a device that could not be retrieved, there were no procedural deaths, and survival was 64 % at three years.

It is difficult to accurately compare survival in the series of percutaneous PVL closure with those in surgical series. As this is a procedure still in its infancy, with surgery often performed without consideration of, or access to, percutaneous closure, those patients presenting for percutaneous therapy are often far more co-morbid than their peers who are taken for surgery. Nevertheless, the available data suggest safety of this approach and substantial functional improvement is enjoyed by patients undergoing percutaneous PVL closure. Given the high risks and poor results of reoperation, percutaneous PVL closure presents a promising treatment that is likely to improve with time and innovation.

Procedural Details
A more thorough description of percutaneous PVL closure techniques can be found elsewhere.14 Briefly, percutaneous mitral PVL closure can be performed via femoral vein access and transseptal puncture, left ventricular (LV) apical access, or retrograde via the femoral artery. Closure of aortic PVL is most effectively accomplished retrograde via the femoral artery. Tricuspid PVL can be accomplished via the jugular vein. The choice of access site should be decided on the basis of PVL location, support required for delivery of the bulky closure devices, and presence of other mechanical prostheses that may interfere with wire-snaring/externalisation. As we perform the majority of our PVL closure procedures without general anaesthesia or endotracheal intubation, minimising TOE-probe dwell time is essential for patient comfort. We therefore rely on ICE (see Figure 6) for transseptal puncture and when possible for PVL guidance (see Figure 6). We have also demonstrated previously the feasibility of integrating computed tomography (CT) data onto the realtime fluoroscopic image using a C-arm based CT acquisition (Syngo DynaCT, Siemens Healthcare, Forchheim, Germany) (see Figure 7).15 These techniques allow us to place the TOE probe only after the device is in place to confirm adequate PVL closure.

Figure 6: Use of Intracardiac Echocardiography to Guide Mitral Paravalvular Leak Closure
Use of Intracardiac Echocardiography to Guide Mitral Paravalvular Leak Closure
Figure 7: Mitral Paravalvular Leak Closure Using Computed Tomography Overlay Guidance
Figure 7: Mitral Paravalvular Leak Closure Using Computed Tomography Overlay Guidance
Choice of Device
There are no devices created specifically for percutaneous PVL closure; those that are used are created for other applications, such as closure of septal defects or vascular plugs (see Figure 8). An important part of planning the percutaneous PVL closure is understanding the shape and size of the defect. We find that given the crescentic shape of PVLs, and the generally round shape of the devices, multiple devices are often necessary to adequately close the leak. It is important, especially in the setting of mechanical valve replacements, to be watchful of impingement on the prosthetic valve apparatus.

Figure 8: Devices Used for Paravalvular Leak Closure
Devices Used for Paravalvular Leak Closure

We most often use the Amplatzer™ Vascular Plug II (AVP II; St. Jude Medical, Minnesota, US), which consists of a nitinol cylinder with a nitinol disc on either side. The AVP I is a single cylinder design, making it less stable and effective in our experience, and the AVP III is not available in the US. We find that the use of atrial septal defect (ASD) occlusion devices is often complicated by the large discs that can interfere with the prosthetic valve, and ventricular septal defect (VSD) closure devices are quite stiff and often result in worsening haemolysis. Patent ductus arteriosus (PDA) occluders are available in limited sizes, but are sometimes helpful when the AVP II discs interfere with valve leaflet motion.

Complications of Paravalvular Leak Closure
Percutaneous PVL closure in trained centres has demonstrated good efficacy and safety. It is important in the performance of these procedures, to be aware of the potential complications in order to plan accordingly.

The atrioventricular node is situated at the junction of the interatrial septum and the interventricular septum. Therefore, closure of PVLs close to this position can be complicated by complete heart block at the time of device implantation. Pre-emptive temporary pacemaker placement may be reasonable in such cases.

Care must be taken to observe mechanical valve function fluoroscopically and by echocardiography to assure that the PVL closure device does not produce valve dysfunction prior to release. In our experience, it is rare that PVL closure cannot be completed due to valve interference, though attempt at different devices and sizes may be necessary for a successful procedure.

In patients for aortic PVL, proximity to the native right and left coronary arteries should be considered, along with the relative size of the aortic sinus. In some cases, it is helpful to take an aortic root angiogram to further define this space prior to the placement of a PVL closure device.

Embolisation of the occluder devices has been reported in <1 % to 5 % of large series’.10,13 A sudden change in symptoms or atrial or ventricular ectopy may be early clues to device embolisation. When it does occur, percutaneous retrieval is usually performed successfully using snare devices and/or bioptomes. Alternatively, if the device is permanently lodged within the LV without significant risk for further mobilisation, consideration can be given to leaving it in place with monitoring by CT or echocardiography during follow-up.10 Echocardiographic follow-up is also important to reassess device placement and integrity of the valve itself as further valve dehiscence over time has been reported.

Patients with cardiac valve replacement may suffer from PVL in the acute, subacute or chronic phases after cardiac surgery. These patients present most commonly with CHF, though a significant number also have debilitating haemolysis. As surgical reoperation carries great risk and chance for PVL recurrence, percutaneous strategies have been developed. These therapies are gaining favour as operators trained in structural cardiac intervention have developed a greater understanding of this procedure and made significant improvements in technique. While no specific trials of percutaneous versus surgical closure exist, many high-volume interventional centres have been taking care of larger numbers of these patients, and consideration may be given to the percutaneous approach as the first-line treatment strategy in carefully selected patients.


  1. Farkouh ME, Domanski M, Fuster V. Revascularization strategies in patients with diabetes. N Engl J Med 2013;368:1455–6.
  2. Stenestrand U, James SK, Lindback J, et al. Safety and efficacy of drug-eluting vs. bare metal stents in patients with diabetes mellitus: long-term follow-up in the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J, 2010;31:177–86.
    Crossref | PubMed
  3. van Geuns JJ, de Jaegere, P., Diletti, R. et al. TCT-429 Shortand intermediate- term clinical outcomes after implantation of everolimus-eluting bioresorbable scaffold in complex lesions : a prospective single-arm study – ABSORB Expand trial. J Am Coll Cardiol 2013;62(suppl):B133.
  4. Niemela M, Kervinen K, Erglis A, et al. Randomized comparison of final kissing balloon dilatation versus no final kissing balloon dilatation in patients with coronary bifurcation lesions treated with main vessel stenting: the Nordic-Baltic Bifurcation Study III. Circulation 2011;123:79–86.
    Crossref | PubMed
  5. Kim MJ, Doh HJ, Choi MK, et al. Skin permeation enhancement of diclofenac by fatty acids, Drug Deliv, 2008;15:373–9.
    Crossref | PubMed
  6. Chabowski A, Gorski J, Glatz JF, et al. Protein-mediated Fatty Acid Uptake in the Heart. Curr Cardiol Rev 2008;4:12–21.
    Crossref | PubMed
  7. Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 2009;360:961–72.
  8. Stone GW, Ellis SG, Cox DA, et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 2004;109:1942–7.
    Crossref | PubMed
  9. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315–23.
    Crossref | PubMed
  10. Finn AV, Nakazawa G, Joner M, et al. Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol 2007;27:1500–10.
    Crossref | PubMed
  11. Nikam N, Steinberg TB, Steinberg DH. Advances in stent technologies and their effect on clinical efficacy and safety. Med Devices (Auckl) 2014;7:165–78.
    Crossref | PubMed
  12. Carrie D, Berland J, Verheye S, et al. A multicenter randomized trial comparing amphilimus- with paclitaxel-eluting stents in de novo native coronary artery lesions. J Am Coll Cardiol 2012;59:1371–6.
    Crossref | PubMed
  13. Airoldi F, Colombo A, Morici N, et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatmen. Circulation 2007;116:745–54.
    Crossref | PubMed
  14. Mehran R, Baber U, Steg PG, et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet 2013;382:1714–22.
    Crossref | PubMed